Skip to main content
Journal cover image

The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.

Publication ,  Journal Article
Pond, GR; Sonpavde, G; de Wit, R; Eisenberger, MA; Tannock, IF; Armstrong, AJ
Published in: Eur Urol
January 2014

The presence of visceral metastases is adversely prognostic in men with metastatic castration-resistant prostate cancer (mCRPC), but the prognostic impact of the site of visceral metastasis is unclear. Men with mCRPC in the TAX 327 phase 3 trial receiving docetaxel or mitoxantrone every 3 wk or weekly docetaxel, each with prednisone, were analyzed retrospectively to study the impact of the site of visceral metastasis on overall survival (OS). Patients were assessed for OS by site of metastases: liver with or without other sites, lung with or without bone or lymph nodes, bone plus lymph nodes, bone only, and lymph nodes only. Cox proportional hazards regression, adjusted for treatment and stratification factors, was performed. Men with liver metastases with or without other metastases had shorter median OS (10.0 mo; 95% confidence interval [CI], 5.4-11.5) than men with lung metastases with or without bone or nodal metastases (median OS: 14.4 mo; 95% CI, 11.5-22.4). Men with lymph node-only disease had the best median OS (26.7 mo; 95% CI, 22.3-34.2), followed by men with bone-only metastases (median OS: 19.0 mo; 95% CI, 18.2-20.7) and bone-plus-node disease (median OS: 15.7 mo; 95% CI, 14.4-17.2). Thus, pattern of spread including site of visceral metastasis confers a differential prognostic impact. These data require validation and may inform trial design and therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

January 2014

Volume

65

Issue

1

Start / End Page

3 / 6

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Retrospective Studies
  • Prostatic Neoplasms, Castration-Resistant
  • Prognosis
  • Neoplasm Metastasis
  • Male
  • Humans
  • Antineoplastic Agents
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pond, G. R., Sonpavde, G., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2014). The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol, 65(1), 3–6. https://doi.org/10.1016/j.eururo.2013.09.024
Pond, Gregory R., Guru Sonpavde, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, and Andrew J. Armstrong. “The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.Eur Urol 65, no. 1 (January 2014): 3–6. https://doi.org/10.1016/j.eururo.2013.09.024.
Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014 Jan;65(1):3–6.
Pond, Gregory R., et al. “The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.Eur Urol, vol. 65, no. 1, Jan. 2014, pp. 3–6. Pubmed, doi:10.1016/j.eururo.2013.09.024.
Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014 Jan;65(1):3–6.
Journal cover image

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

January 2014

Volume

65

Issue

1

Start / End Page

3 / 6

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Retrospective Studies
  • Prostatic Neoplasms, Castration-Resistant
  • Prognosis
  • Neoplasm Metastasis
  • Male
  • Humans
  • Antineoplastic Agents
  • 3202 Clinical sciences
  • 1103 Clinical Sciences